GPT2 and liposarcoma: MDM2-ALT1 and MDM2-ALT2 were first described to be expressed in soft tissue sarcoma samples, including liposarcomas, in 2001 by Bartel and colleagues, but without reporting correlation with MDM2 amplification [28].